STOCK TITAN

Armistice Capital takes 9.99% stake in Imunon (IMNN)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Imunon, Inc. reported that Armistice Capital, LLC and Steven Boyd beneficially own 349,917 shares of common stock, representing 9.99% of the class as of 12/31/2025. The filing states shared voting and dispositive power over the 349,917 shares and notes that the Master Fund has the right to receive dividends or sale proceeds.

Positive

  • None.

Negative

  • None.

Insights

Armistice reports a 9.99% stake in Imunon with shared voting power.

The filing lists 349,917 shares beneficially owned with shared voting and shared dispositive power as of 12/31/2025. This reflects a passive ownership disclosure under Schedule 13G rather than an active Schedule 13D acquisition narrative.

The statement also notes the Master Fund's right to receive dividends or sale proceeds; subsequent filings would clarify if ownership or intent changes.

Disclosure signals a near-10% stake by an institutional investor, useful for shareholder registers and proxy tallies.

The report attributes shared voting and dispositive power to Armistice/Steven Boyd for the 349,917 shares. The filing is a joint filing by Armistice Capital, LLC and Steven Boyd and is signed on 02/17/2026.

Any effect on governance depends on future filings or voting activity; timing and any planned transactions are not stated here.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake did Armistice Capital report in IMNN?

Armistice Capital reported beneficial ownership of 349,917 shares, equal to 9.99% of Imunon's common stock as of 12/31/2025. The filing attributes shared voting and dispositive power over those shares to Armistice and Steven Boyd.

Does the Schedule 13G indicate control of Imunon (IMNN)?

The filing shows shared voting power for 349,917 shares, but a Schedule 13G typically reflects passive intent. The document does not state that Armistice exercises control or has changed intent to influence management.

Who else benefits from the IMNN shares held by Armistice?

The filing states the Master Fund, a Cayman Islands exempted company and an Armistice advisory client, has the right to receive dividends or proceeds from the reported securities. No other beneficiaries are named.

When was the IMNN ownership disclosure signed?

The joint Schedule 13G was signed by Steven Boyd on 02/17/2026. The ownership figures are reported as of 12/31/2025 in the filing.

Does the filing show sole voting or dispositive power for IMNN shares?

No. The filing reports 0 sole voting power and 0 sole dispositive power; both vote and dispositive powers are reported as shared for 349,917 shares.
Imunon Inc

NASDAQ:IMNN

IMNN Rankings

IMNN Latest News

IMNN Latest SEC Filings

IMNN Stock Data

11.09M
3.04M
Biotechnology
Pharmaceutical Preparations
Link
United States
LAWRENCEVILLE